Somewhat Positive Media Coverage Somewhat Unlikely to Impact Applied Genetic Technologies (AGTC) Stock Price
News stories about Applied Genetic Technologies (NASDAQ:AGTC) have trended somewhat positive on Monday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Applied Genetic Technologies earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.9801339558176 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Applied Genetic Technologies (NASDAQ AGTC) opened at $3.60 on Monday. The company has a market capitalization of $63.38, a PE ratio of -13.85 and a beta of 1.62. Applied Genetic Technologies has a 52-week low of $3.25 and a 52-week high of $10.15.
A number of equities analysts have recently weighed in on the company. Wedbush reaffirmed an “outperform” rating and issued a $9.00 price objective on shares of Applied Genetic Technologies in a research note on Wednesday, November 8th. Stifel Nicolaus dropped their price objective on Applied Genetic Technologies from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, September 14th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective (down previously from $16.00) on shares of Applied Genetic Technologies in a research note on Thursday, September 14th. Cantor Fitzgerald dropped their price objective on Applied Genetic Technologies from $15.00 to $9.00 and set a “neutral” rating for the company in a research note on Thursday, September 14th. Finally, Zacks Investment Research lowered Applied Genetic Technologies from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 31st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $10.17.
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).
Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.